Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with FDA-supported analysis suggesting encouraging early signals.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction ...
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM –– Company plans to ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac ...
Results from the GLISTEN study, the largest investigational trial of pruritus in primary biliary cholangitis (PBC), indicate ...
At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that ...
CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual ...
Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback